Literature DB >> 17579611

Association and linkage of allelic variants of the dopamine transporter gene in ADHD.

S Friedel1, K Saar, S Sauer, A Dempfle, S Walitza, T Renner, M Romanos, C Freitag, C Seitz, H Palmason, A Scherag, C Windemuth-Kieselbach, B G Schimmelmann, C Wewetzer, J Meyer, A Warnke, K P Lesch, R Reinhardt, B Herpertz-Dahlmann, M Linder, A Hinney, H Remschmidt, H Schäfer, K Konrad, N Hübner, J Hebebrand.   

Abstract

Previously, we had reported a genome-wide scan for attention-deficit/hyperactivity disorder (ADHD) in 102 families with affected sibs of German ancestry; the highest multipoint LOD score of 4.75 was obtained on chromosome 5p13 (parametric HLOD analysis under a dominant model) near the dopamine transporter gene (DAT1). We genotyped 30 single nucleotide polymorphisms (SNPs) in this candidate gene and its 5' region in 329 families (including the 102 initial families) with 523 affected offspring. We found that (1) SNP rs463379 was significantly associated with ADHD upon correction for multiple testing (P=0.0046); (2) the global P-value for association of haplotypes was significant for block two upon correction for all (n=3) tested blocks (P=0.0048); (3) within block two we detected a nominal P=0.000034 for one specific marker combination. This CGC haplotype showed relative risks of 1.95 and 2.43 for heterozygous and homozygous carriers, respectively; and (4) finally, our linkage data and the genotype-IBD sharing test (GIST) suggest that genetic variation at the DAT1 locus explains our linkage peak and that rs463379 (P<0.05) is the only SNP of the above haplotype that contributed to the linkage signal. In sum, we have accumulated evidence that genetic variation at the DAT1 locus underlies our ADHD linkage peak on chromosome 5; additionally solid association for a single SNP and a haplotype were shown. Future studies are required to assess if variation at this locus also explains other positive linkage results obtained for chromosome 5p.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579611     DOI: 10.1038/sj.mp.4001986

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  26 in total

Review 1.  Genetic factors modulating the response to stimulant drugs in humans.

Authors:  Amy B Hart; Harriet de Wit; Abraham A Palmer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 2.  Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Authors:  Tanya E Froehlich; James J McGough; Mark A Stein
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 3.  Genetic aspects in attention-deficit/hyperactivity disorder.

Authors:  O Albayrak; S Friedel; B G Schimmelmann; A Hinney; J Hebebrand
Journal:  J Neural Transm (Vienna)       Date:  2008-01-16       Impact factor: 3.575

4.  Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type.

Authors:  T L da Silva; T G Pianca; T Roman; M H Hutz; S V Faraone; M Schmitz; L A Rohde
Journal:  J Neural Transm (Vienna)       Date:  2008-01-16       Impact factor: 3.575

5.  Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder.

Authors:  Kaixin Zhou; Astrid Dempfle; Mauricio Arcos-Burgos; Steven C Bakker; Tobias Banaschewski; Joseph Biederman; Jan Buitelaar; F Xavier Castellanos; Alysa Doyle; Richard P Ebstein; Jenny Ekholm; Paola Forabosco; Barbara Franke; Christine Freitag; Susann Friedel; Michael Gill; Johannes Hebebrand; Anke Hinney; Christian Jacob; Klaus Peter Lesch; Sandra K Loo; Francisco Lopera; James T McCracken; James J McGough; Jobst Meyer; Eric Mick; Ana Miranda; Maximilian Muenke; Fernando Mulas; Stanley F Nelson; T Trang Nguyen; Robert D Oades; Matthew N Ogdie; Juan David Palacio; David Pineda; Andreas Reif; Tobias J Renner; Herbert Roeyers; Marcel Romanos; Aribert Rothenberger; Helmut Schäfer; Joseph Sergeant; Richard J Sinke; Susan L Smalley; Edmund Sonuga-Barke; Hans-Christoph Steinhausen; Emma van der Meulen; Susanne Walitza; Andreas Warnke; Cathryn M Lewis; Stephen V Faraone; Philip Asherson
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-12-05       Impact factor: 3.568

6.  Genetic associations with reflexive visual attention in infancy and childhood.

Authors:  Rebecca A Lundwall; James L Dannemiller; H Hill Goldsmith
Journal:  Dev Sci       Date:  2015-11-27

Review 7.  Molecular genetics of attention-deficit/hyperactivity disorder: an overview.

Authors:  Tobias Banaschewski; Katja Becker; Susann Scherag; Barbara Franke; David Coghill
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-02-10       Impact factor: 4.785

Review 8.  Does the difference between physically active and couch potato lie in the dopamine system?

Authors:  Amy M Knab; J Timothy Lightfoot
Journal:  Int J Biol Sci       Date:  2010-03-09       Impact factor: 6.580

Review 9.  The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy.

Authors:  Mark A Stein; James J McGough
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-04

10.  Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice.

Authors:  Susan B Powell; Jared W Young; Jacob C Ong; Marc G Caron; Mark A Geyer
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.